How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
17h
Will AI models achieve the ability to improve autonomously? Leading labs say the scenario is near
AI developers are striving for self-improvement, aiming for technology that can enhance itself. Concerns about AI escaping ...
AI can help with those tasks. Recursive self-improvement takes that a step further: An AI helps build a successor that is ...
Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Two solid-value approaches, one well-built ETF. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Artificial intelligence (AI) often grabs headlines through chatbots like ChatGPT, but for companies using AI, most real-world business value comes from less visible applications. Learn about how to ...
AI CTO and systems builder. CTO of Archdesk; founder of Lextron.ai, Inclify and Rejsomat. I write on enterprise AI, agents and Joule Wars. RSI AI refers to artificial intelligence capable of recursive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results